In the race to get a CAR-T therapeutic to the market, Novartis announced that the U.S. FDA accepted its BLA filing and granted priority review for CTL019.

TG Therapeutics Inc. said a combination of its experimental cancer drug ublituximab and AbbVie Inc.’s Imbruvica outperformed Imbruvica alone in high-risk leukemia patients.

Novartis, lagging some other big drugmakers in the first wave of immunotherapy drugs that are revolutionizing cancer treatment, is focusing on the next wave of immune system-boosting medicines.

It’s expected that a large number of clinical trials will result in failure. 2016 saw numerous trial failures, but analysts at The Motley Fool selected seven failures that are expected to have a direct impact on the forward outlooks of the companies involved.

Novartis’ experimental CAR-T therapy CLT019 sent 82 percent of patients’ blood cancer into remission, according to interim data presented at the American Society of Hematology.

Juno Therapeutics Inc. said two more patients had died after suffering brain swelling during a trial of its experimental genetically engineered leukemia drug.

Novartis AG is dissolving its Cell and Gene Therapy Unit, according to Endpoints News, citing a note sent to 400 employees by division president Usman Azam.

BOSTON, June 20, 2016 /PRNewswire/ — Researchers at the Human Microbiology Institute (HMI) have discovered a novel bacteria in the saliva of children with acute leukemia that they say could be linked to deadly, drug-resistant pneumonia in patients with blood cancer. Photo – In an abstract presented over the weekend at ASM Microbe 2016, the […]

Jazz Pharmaceuticals struck a deal to acquire Celator Pharmaceuticals and its promising leukemia drug for $1.5 billion.

A second baby with aggressive leukemia has been treated in London with “designer immune cells” developed by Cellectis and, six months after treatment, she remains in remission.